EOLS (Evolus) Moat Score: 5/10 (As of Jul. 02, 2026)


EOLS Evolus Inc EOLS
71 GF Score
Price $6.75
GF Value $13.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Evolus Moat Score?

Evolus EOLS -2.74% 71 Moat Score is 5 as of Jul. 02, 2026. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Evolus ranks better than 94.67% on this metric.

Evolus has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Evolus has Narrow Moat: Evolus has a solid narrow moat due to its proprietary technology in aesthetic medicine and some brand recognition. However, it faces strong competition and lacks significant regulatory barriers or economies of scale to achieve a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Evolus might have Narrow Moat - Solid narrow moat.

Evolus  (NAS:EOLS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Evolus Moat Score Related Terms

EOLS vs NIKA, EBS, ELTP: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Moat Score distribution charts can be found below:

* The bar in red indicates where Evolus's Moat Score falls into.


EOLS
71GF Score
Evolus Inc EOLS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Evolus (EOLS) has a Moat Score of 5 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Evolus ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Evolus' Moat Score too high?
Evolus' current Moat Score is 5. Based on the distribution chart, Evolus ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Moat Score compare to NIKA and EBS?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #55 out of 1031 companies for Moat Score. This places Evolus in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Evolus's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.62, compared to a current price of $6.75 — trading 50.4% below its estimated fair value. The current Moat Score is 5. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Evolus (EOLS), the current Moat Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $6.75 is trading 50.4% below its estimated GF Value™ of $13.62. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Moat Score: 5
  • GF Value™: $13.62 vs. price of $6.75 (50.4% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score

Get the complete analysis for EOLS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75
Price
$13.62
GF Value